Cargando…
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
BACKGROUND: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience relapses with a median progression-free survival of 12–18 months. There...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024442/ https://www.ncbi.nlm.nih.gov/pubmed/27634150 http://dx.doi.org/10.1186/s12967-016-1027-1 |